MX386181B - Formas cristalinas de un inhibidor de quinasa janus - Google Patents

Formas cristalinas de un inhibidor de quinasa janus

Info

Publication number
MX386181B
MX386181B MX2019007462A MX2019007462A MX386181B MX 386181 B MX386181 B MX 386181B MX 2019007462 A MX2019007462 A MX 2019007462A MX 2019007462 A MX2019007462 A MX 2019007462A MX 386181 B MX386181 B MX 386181B
Authority
MX
Mexico
Prior art keywords
crystalline forms
janus kinase
kinase inhibitor
methods
inhibitor
Prior art date
Application number
MX2019007462A
Other languages
English (en)
Spanish (es)
Other versions
MX2019007462A (es
Inventor
Noriaki Shimoyama
Ryuhei Okura
Satoru Noji
Yukihiro Kamiya
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2019007462A publication Critical patent/MX2019007462A/es
Publication of MX386181B publication Critical patent/MX386181B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019007462A 2016-12-21 2017-12-20 Formas cristalinas de un inhibidor de quinasa janus MX386181B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2019007462A MX2019007462A (es) 2019-08-29
MX386181B true MX386181B (es) 2025-03-18

Family

ID=60991475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007462A MX386181B (es) 2016-12-21 2017-12-20 Formas cristalinas de un inhibidor de quinasa janus

Country Status (13)

Country Link
US (1) US11339181B2 (enExample)
EP (1) EP3559003B1 (enExample)
JP (3) JP2020502224A (enExample)
KR (1) KR102788829B1 (enExample)
CN (2) CN110325536A (enExample)
AU (1) AU2017380213B2 (enExample)
BR (1) BR112019012210A2 (enExample)
CA (1) CA3044771A1 (enExample)
ES (1) ES2926986T3 (enExample)
IL (1) IL267393B2 (enExample)
MX (1) MX386181B (enExample)
TW (1) TWI822666B (enExample)
WO (1) WO2018117153A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3560932T3 (pl) 2016-12-21 2026-06-29 Japan Tobacco Inc. Sposób wytwarzania pochodnych 7H‑pirolo[2,3‑d]pirymidyny i ich syntetycznych produktów pośrednich
JP7597714B2 (ja) * 2019-08-07 2024-12-10 ロート製薬株式会社 涙液分泌促進用眼科組成物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CA3210150A1 (en) * 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
JP7807247B2 (ja) * 2021-02-05 2026-01-27 ロート製薬株式会社 シェーグレン症候群治療剤
KR20240027044A (ko) * 2021-07-30 2024-02-29 일라이 릴리 앤드 캄파니 바리시티닙을 사용한 손 습진의 치료
AU2024229918A1 (en) * 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500666A (ja) * 2005-07-07 2009-01-08 トムソン ライセンシング 対応スタンドを備えたフラット画面ディスプレイシステム
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
BRPI1012108B8 (pt) * 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
BR112017026173A2 (pt) * 2015-07-07 2018-08-14 Japan Tobacco, Inc. Método para produção de derivado de 7h-pirrolo [2,3-d]pirimidina e intermediário do mesmo

Also Published As

Publication number Publication date
CN121045220A (zh) 2025-12-02
US20200017527A1 (en) 2020-01-16
BR112019012210A2 (pt) 2019-11-12
KR20190092440A (ko) 2019-08-07
CN110325536A (zh) 2019-10-11
JP2023024729A (ja) 2023-02-16
MX2019007462A (es) 2019-08-29
EP3559003B1 (en) 2022-08-24
JP2024161449A (ja) 2024-11-19
AU2017380213B2 (en) 2022-01-06
RU2019122566A3 (enExample) 2021-12-22
US11339181B2 (en) 2022-05-24
IL267393B2 (en) 2023-07-01
TW201829423A (zh) 2018-08-16
WO2018117153A1 (en) 2018-06-28
EP3559003A1 (en) 2019-10-30
JP2020502224A (ja) 2020-01-23
IL267393A (en) 2019-08-29
ES2926986T3 (es) 2022-10-31
IL267393B1 (en) 2023-03-01
AU2017380213A1 (en) 2019-05-23
TWI822666B (zh) 2023-11-21
RU2019122566A (ru) 2021-01-22
CA3044771A1 (en) 2018-06-28
KR102788829B1 (ko) 2025-03-31

Similar Documents

Publication Publication Date Title
MX2019007462A (es) Formas cristalinas de un inhibidor de quinasa janus.
MX2024005335A (es) Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos.
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
PH12019500393A1 (en) Substituted pyrrolizine compounds and uses thereof
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MY200328A (en) Kinase inhibitors and uses thereof
UY35861A (es) ?acrilamidas de pirrolo[2,3-d]pirimidini lo, pirrolo[2,3-b]irazinilo y pirrolo[2,3-d]piridinilo?
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
WO2016063294A3 (en) Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
AU2017319080A1 (en) Pyrazolo[1,5-a]pyrimidine compound
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
WO2016066726A3 (en) Active acrylamides
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
MX2019002627A (es) Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo.
JOP20190080A1 (ar) مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EA201791276A1 (ru) Замещенные пиперидином трициклические производные пиразоло[1,5-a]пиримидина с ингибирующей активностью в отношении репликации респираторно-синцитиального вируса (rsv)